IMVT — Immunovant, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1764013 ·
Last close
$33.83
Market Cap
$6.95B
52W High
$36.28
52W Low
$22.79
ADV30
2,270,812
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 0 | — | -114,362,000 | -110,635,000 | 1,052,392,000 | 994,525,000 | 66,257,000 |
| Sep 2025 | 0 | — | -131,762,000 | -126,502,000 | 582,959,000 | 521,870,000 | 63,254,000 |
| Jun 2025 | 0 | — | -127,224,000 | -120,613,000 | 661,440,000 | 598,912,000 | 52,900,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-422,888,000
Investing CF
$-201,000
Financing CF
$1,042,728,000
CapEx
$-577,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.69
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,597,273,000
Inventory
—
Receivables
$1,643,000
ST Investments
—
EBIT TTM
$-487,173,000
Pretax Income TTM
$-460,557,000
Interest Exp TTM
—
Analysts
17
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -532,902,000 | -505,606,000 | 957,014,000 | 104,422,000 | — | -407,310,000 |
| Mar 2025 | 0 | -438,152,000 | -413,840,000 | 776,222,000 | 68,775,000 | — | -375,874,000 |
| Mar 2024 | 0 | -270,209,000 | -259,336,000 | 666,365,000 | 48,608,000 | — | -214,227,000 |
| Mar 2023 | 0 | -208,276,000 | -210,960,000 | 405,838,000 | 43,344,000 | — | -188,193,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-267,152,000
OpCashFlow TTM
$0
Assets (Latest)
$776,222,000
Forward EPS
$-2.40
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCVX | Vaxcyte, Inc. | $7.24B | $50.11 | — |
| KYMR | Kymera Therapeutics, Inc. | $6.64B | $80.77 | — |
| QGEN | QIAGEN N.V. | $7.33B | $35.54 | — |
| RGEN | REPLIGEN CORP | $6.50B | $115.19 | — |
| TECH | BIO-TECHNE Corp | $7.51B | $47.97 | — |
News headlines (Yahoo Finance, 1h cache)
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
2026-05-24 14:39 · Yahoo
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
2026-05-24 14:33 · Yahoo
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
2026-05-23 22:40 · Yahoo
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
2026-05-23 22:33 · Yahoo
Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider Losses - Has The Bull Case Changed?
2026-05-22 05:15 · Yahoo
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
2026-05-21 13:19 · Yahoo
Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial
2026-05-21 02:49 · Yahoo
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
2026-05-20 20:38 · Yahoo
These Two Biotech Stocks Rocketed — And One Just Broke Out
2026-05-20 20:11 · Yahoo
Sector Update: Healthcare Stocks Mixed Late Afternoon
2026-05-20 19:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.